干燥综合征治疗的现状与未来  

The current status and future of treatment for Sjögren’s syndrome

作　　者：谭震[1] 厉小梅 TAN Zhen;LI Xiao-mei(Department of Rheumatology and Immunology,The First Affiliated Hospital of University of Science and Technology of China,Hefei 230001,China)

机构地区：[1]中国科学技术大学附属第一医院风湿免疫科,合肥230001

出　　处：《中国新药杂志》2023年第22期2234-2239,共6页Chinese Journal of New Drugs

基　　金：国家自然科学基金项目(U21A20365);“科大新医学”联合基金项目(WK9110000148)。

摘　　要：干燥综合征(Sjögren’s syndrome,SS)是一种以淋巴细胞浸润外分泌腺为主要病理表现的自身免疫性疾病,可出现多系统受累。目前,SS的腺体治疗以局部为主,系统性受累的治疗方案主要借鉴其他自身免疫性疾病,尚无获批的针对性药物。本文系统地综述了SS当前的治疗方案,并对正在进行临床试验、未来可能应用于SS的治疗药物进行了总结,包括靶向B细胞活化因子(BAFF)、CD40、调节性T细胞/辅助性T细胞17(Treg/Th17)、Bruton酪氨酸激酶(BTK)、JAK-STAT通路的药物以及间充质干细胞等。靶向药物和联合治疗应该是未来研究的重点。Sjögren’s syndrome(SS)is an autoimmune disease characterized by lymphocyte infiltration of exocrine glands,which may involve multiple systems.At present,the glandular treatment of SS is mainly localized,and the treatment regimen for systemic involvement is mainly based on those for other autoimmune diseases,and there is no approved targeted drug.In this study,we systematically reviewed the current treatment regimens for SS and summarized the drugs that are undergoing clinical trials and may be applied to SS in the future,including drugs targeting BAFF,CD40,Treg/Th17,BTK,JAK-STAT,and mesenchymal stem cells.Targeted drugs and combination therapy should be the focus of future research.

关 键 词：干燥综合征 局部治疗 系统治疗 靶向药物 

分 类 号：R979.5[医药卫生—药品]